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Abstract 
Structure–activity relationship studies of diaryl amine-type KSP inhibitors were carried out. 
Diaryl amine derivatives with a pyridine ring or urea group were less active when compared 
with the parent carboline and carbazole derivatives. Optimization studies of a lactam-fused 
diphenylamine-type KSP inhibitor revealed that the aniline NH group and 3-CF3 phenyl group 
were indispensable for potent KSP inhibition. Modification with a seven-membered 
lactam-fused phenyl group and a 4-(trifluoromethyl)pyridin-2-yl group improved aqueous 
solubility while maintaining potent KSP inhibitory activity. From these studies, we identified 
novel diaryl amine-type KSP inhibitors with a favorable balance of potency and solubility. 
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1. Introduction 
Kinesins constitute a superfamily of molecular motor proteins to move along 
microtubules.1 Mitotic kinesins are involved in cell division.2 Non-mitotic kinesins are 
principally involved in intracellular transport of organelles and vesicles.3 The kinesin spindle 
protein (KSP; also known as Eg5) is the mitotic kinesin that belongs to the kinesin-5 family. 
The structure of KSP is comprised of three parts: an N-terminal motor domain, a central 
-helical coiled coil stalk domain, and a C-terminal tail domain.4 The N-terminal motor 
domain contains a catalytic site for ATP hydrolysis and microtubule binding region. KSP 
moves toward the plus end of the microtubule, just like other kinesins with an N-terminal 
motor domain, using the energy generated from the hydrolysis of ATP.5 The KSP movement is 
required for centrosome separation and bipolar spindle formation during cell division. 
Inhibition of KSP leads to mitotic arrest in the prometaphase with the formation of the 
monopolar spindle and subsequent apoptotic cell death.6-9 Therefore, KSP inhibitors are 
expected to be favorable agents for cancer chemotherapy without neurotoxic side effects.10-13 
Recently, we reported that carbazole derivative 1 with the 2-CF3 group showed potent KSP 
inhibitory activity (Figure 1).14 Carbazole derivatives, with a lactam ring (2) or urea group 
(4c), and the -carboline derivative 3a were also identified as highly potent KSP inhibitors by 
structure–activity relationship studies of 1.15 However, these inhibitors exhibited limited 
solubility in the aqueous solvents employed for in vivo studies. To satisfy the potent 
inhibitory activity requirements as well as better solubility in aqueous solution, we have 
designed diphenylamine derivatives such as 5a by modification of the planar carbazole-type 
inhibitor 2.16 Diphenylamine 5a exhibited better solubility than carbazole 2 while maintaining 
potent KSP inhibitory activity. Structural analysis by single crystal X-ray diffraction studies 
and free energy calculations demonstrated that the improved solubility of 5a is attributed to 
fewer van der Waals interactions in the crystal packing, as well as a hydrogen-bond acceptor 
nitrogen in the aniline moiety for favorable solvation. Interestingly, compound 5a possibly 
binds to the interface of the 4 and 6 of KSP in an ATP-competitive manner, whereas most 
KSP inhibitors (e.g., monastrol, S-trityl-L-cysteine) bind to the allosteric pocket formed by 
helices 2, 3 and loop L5 to show ATP-uncompetitive behavior.17-19 Replacing the 
right-hand 3-CF3-phenyl group in 5a with a pyridine ring provided a more soluble KSP 
inhibitor 6; however, this compound showed slightly lower potency than 5a.16 In this article, 
we describe the structure–activity relationship study for novel diaryl amine-type KSP 
inhibitors with high potency and aqueous solubility. For this purpose, we performed: (i) 
modification of ring-fused indoles such as 3a and 4c using the same approach employed for 
the development of 5a and (ii) intensive optimization studies of diphenylamine 5a. 
 
2. Results and discussion 
2.1. Investigation of diaryl amine-type KSP inhibitors by modification of ring-fused 
scaffolds 
We speculated that the poor solubility of carboline and carbazole derivatives would be 
attributable to the significant intermolecular interactions in the crystals (e.g., – stacking 
interactions) as seen for compound 2.16 To disrupt the possible crystal packing of compounds 
3a and 4c, the design of less planar analogs was expected to be a promising approach.20 
Therefore, we designed diaryl amine derivatives 7 and 8, in which the pyrrole C–C bond in 
the central part of carbolines 3 and carbazoles 4 was cleaved (Figure 2). Diaryl amines 7a,b 
with a pyridine ring were designed based on carbolines 3a,b with potent KSP inhibitory 
activity (Figure 2A). Diphenylamines 8a–f with a nitro, amino or urea group at the 3- or 
4-position on the left-hand phenyl ring were similarly investigated, which represent the 
cleaved analogs of carbazoles 4b–f (Figure 2B). Diaryl amine derivatives 7a,b and 8a,d were 
prepared by palladium-catalyzed N-arylation using aryl bromides 9 and substituted anilines 10 
(Scheme 1).21 For the preparation of compounds 8c,f with a urea group, nitro derivatives 8a,d 
were reduced to the corresponding amines 8b,e using Pd/C and ammonium formate, which 
were converted to the expected compounds 8c,f by KOCN. 
First, KSP inhibitory activity of compounds 7a,b, with a pyridine ring in the left-hand part, 
was comparatively assessed with the parent carboline-type inhibitors 3a,b (Table 1). 
Unfortunately, the cleavage of the pyrrole C–C bond in carboline led to loss of KSP ATPase 
inhibitory activity at 6.3 M. The solubility of these compounds was evaluated by a 
thermodynamic method.22 A mixture of EtOH–phosphate buffer (pH 7.4) (1:1) [50% EtOH] 
and phosphate buffer (pH 7.4) were employed as aqueous media.22 In these solutions, the 
parent carbazole-type inhibitor 1 was moderately soluble (0.424 mg/mL) and insoluble (<1 
g/mL), respectively. N-(Pyridin-3-yl)amine 7a showed the anticipated improvement in 
thermodynamic solubility, being 30 times more soluble in 50% EtOH (14.3 mg/mL) 
compared with the corresponding carboline 3a. N-(Pyridin-4-yl)amine 7b also exhibited 
approximately 14 times greater solubility in 50% EtOH (24.0 mg/mL) than the parent 
carboline 3b. Of note, compound 7b had moderate solubility (264 g/mL) even in phosphate 
buffer, which was 80 times or more soluble compared with 3b and 3a, respectively. Although 
these pyridinylamine derivatives 7a,b were inert in KSP inhibition, it was suggested that 
cleavage of the pyrrole C–C bond in carboline and carbazole derivatives could be a promising 
approach to improve the solubility in aqueous solution. 
Diphenylamine derivatives 8a–f with a nitro, amino or urea group at the 3- or 4-position on 
the left-hand phenyl group were next examined (Table 2). The 3-substituted anilines 8a–c 
showed no KSP inhibitory activity at 6.3 M. Among the 4-substituted analogs, compound 8f 
with a urea group exhibited moderate inhibitory activity (IC50 = 0.39 M), while compounds 
8d,e with a nitro or amino group had weak or no potency. The potency of 8f was 
approximately three times lower than that of the parent carbazole 4f. 
 
2.2. Optimization studies of lactam-fused diaryl amine-type KSP inhibitors 
Next, we investigated the structure–activity relationship and the further refinement of 5a 
for novel potent KSP inhibitors in terms of: (i) the linkage between the two aryl groups, (ii) 
the substituent on the right-hand phenyl group, (iii) the left-hand heterocycle, and (iv) the 
right-hand aromatic heterocycle (Figure 3).  
A series of diaryl amine derivatives 5 and 11–14 were prepared by Buchwald–Hartwig 
N-arylation using aryl bromides or triflates 9 and substituted anilines 10, except for the 
compounds (11j,l,n and 12c,k) indicated below (Scheme 1).21 Diphenylether derivative 17a 
was obtained by treatment of phenol derivative 15 with diaryliodonium tetrafluoroborate 16 in 
the presence of KOt-Bu.23 Diphenylsulfide derivatives 20a,b were prepared by the 
copper-catalyzed C–S bond-forming reaction using aryl thiol 18 and CF3-substituted 
iodobenzenes 19a,b.24 Compounds 11j, 11l, 11n and 12k were obtained by simple 
transformations including BBr3-mediated demethylation of 11h, Zn-mediated reduction of 
11k, saponification of 11m, and thiocarbonylation of 5a using Lawesson’s reagent,25 
respectively. Compound 12c was prepared by treatment of 12a with O2 in the presence of 
Pd(OAc)2. 
We initially investigated the type of heteroatom in the central part of diphenylamine 5a and 
the position of a substituent on the right-hand phenyl group (Table 3). Replacing the bridging 
NH group in compound 5a with oxygen (17a,b: ether) or sulfur (20a,b: thioether) resulted in 
a significant reduction or loss of KSP inhibitory activity. This indicates that the aniline NH 
group of 5a is an indispensable functional group as a hydrogen-bond donor, which is 
supported by our previous modeling study.16 Regarding the position of CF3 group on the 
right-hand phenyl ring of 5a, 4-CF3 compound 5b was approximately 7 times less potent than 
5a and no KSP inhibition of 2-CF3 compound 5c was observed. 
Next, the structure–activity relationship was examined by replacing 3-substituents on the 
right-hand phenyl group in 5a (Table 4). Among compounds 11a–d with or without a 3-alkyl 
substituent, the tert-butyl derivative 11d exhibited the most potent inhibitory activity (IC50 = 
0.16 M). The structure–activity relationship of the simple alkyl group correlated with that of 
the carbazole-type KSP inhibitors, suggesting that carbazoles (1 and 2) and diphenylamines 
(5a and 11d) may occupy the same binding site of KSP.15,16 Substitution with 3,5-di-CF3 (11e), 
3-phenyl (11f), 3-phenoxy (11g) and 3-methoxy (11h) groups were not effective. Introduction 
of a polar substituent such as 3-hydroxy (11j), 3-amino (11l), 3-methoxycarbonyl (11m), or 
3-carboxylate (11n) also gave rise to inactive compounds. 3-Trifluoromethyloxy (11i) and 
3-nitro (11k) derivatives showed moderate inhibitory activity. It is inferred from these data 
that the substituent at the 3-position on the right-hand phenyl part is buried in a relatively 
large hydrophobic pocket of KSP. The possible binding mode of 11d to the interface of the 4 
and 6 helices of KSP is shown in Figure 5. The tert-butyl group of 11d was buried in the 
deep hydrophobic pocket formed by Tyr104, Gly296, Ile299, Thr300, Ile332, Tyr352, Ala353, 
and Ala356. Low desolvation energy of tert-butyl group compared with smaller alkyl groups 
may also contribute to the favorable binding of 11d to KSP. 
In the left part of the molecule, the position of accessory amide group was crucial for the 
potency (Table 5). Compounds 12a–d with an amide group at the 3-position were less active 
or inactive, while the parent compound 5a with the 4-position amide group showed potent 
KSP inhibitory activity. A five-membered ring thiocarbamate 12g exhibited moderate 
inhibitory activity (IC50 = 0.81 M) in contrast to the ineffectiveness in lactam derivative 12e 
and carbamate derivative 12f, suggesting that the introduction of a sulfur atom into the lactam 
ring had favorable effects on the bioactivity. The addition of a sulfur atom (12i) into the 
six-membered lactam of 5a also maintained potent KSP inhibitory activity (IC50 = 0.051 M), 
whereas an oxygen atom (12h) decreased the inhibitory activity. The loss of activity in the 
N-methylamide derivative 12j indicates that the lactam NH group at this position is essential 
for KSP inhibition. Compound 12k, with a thioamide group, had slightly reduced potency 
(IC50 = 0.19 M) compared with 5a. Compound 12l, with a seven-membered lactam, showed 
approximately equipotent KSP inhibitory activity (IC50 = 0.050 M) to 5a, suggesting that 
some flexibility of the lactam carbonyl placement is tolerated. Substitution with a fluorine 
group on the 5- or 6-position (12m,n) resulted in a reduction in the inhibitory activity, 
suggesting that modification at these positions was inappropriate for favorable interactions 
with KSP. 
 
2.3. Analysis of aqueous solubility of potent KSP inhibitors and further optimization 
The thermodynamic solubility of potent diphenylamine derivatives 12i,l in aqueous media 
was next evaluated (Table 6).22 Diphenylamine 12i with a thiomorpholin-3-one structure was 
slightly less soluble (1.70 mg/mL in 50% EtOH) than the parent compound 5a. The longer 
retention time on a reversed-phase HPLC column (28.2 min) of compound 12i indicated that 
the introduction of a sulfur atom into the lactam ring of 5a resulted in the increased 
hydrophobicity, thereby lowering the solubility in aqueous media. Diphenylamine 12l with a 
seven-membered lactam ring was approximately four times more soluble (7.39 mg/mL in 
50% EtOH) than 5a, although a high CLogP value and HPLC retention time indicated higher 
hydrophobicity. The lower melting point of compound 12l (140 C) suggested that the weak 
crystal packing mainly contributed to the observed improvement in solubility. These results 
indicated that the seven-membered lactam ring on the left-hand phenyl group was a promising 
structural unit for the development of KSP inhibitors that have a favorable balance of 
bioactivity and aqueous solubility. 
As such, we identified benzothiomorpholin-3-one 12i and benzoazepin-2-one 12l as potent 
KSP inhibitors using structure–activity relationship studies of fused heterocycles on the 
left-hand phenyl group. Compound 12l represents the lead compound for further structural 
refinements because of the improved solubility. Separately, examination of the right-hand 
phenyl group identified 6-pyridine derivative 6 with potent KSP inhibitory activity and 
improved aqueous solubility.16 On the basis of these promising components, two diaryl amine 
derivatives were then designed (Figure 4). Diaryl amine 13 was designed based on compound 
12i with a thiomorpholin-3-one structure and compound 6 with a 6-pyridine ring. Diaryl 
amine 14 was similarly designed based on compounds 12l and 6. 
Thiomorpholin-3-one 13 exhibited the most potent KSP inhibitory activity (IC50 = 0.035 
M) among the diaryl amine-type inhibitors that were examined in this study (Table 6). 
However, compound 13 was less soluble in 50% EtOH (0.669 mg/mL) and in phosphate 
buffer (1.11 g/mL) than the parent compound 6. The high melting point of compound 13 
(217 C) indicated that the tight crystal packing might cause this decrease in aqueous 
solubility. Benzoazepin-2-one 14 maintained highly potent KSP inhibitory activity (IC50 = 
0.050 M) as seen for the parent compounds 5a, 6 and 12l. Compound 14 exhibited greater 
solubility in 50% EtOH (4.82 mg/mL) and in phosphate buffer (8.07 g/mL) than the 
corresponding compound 6. Of note, solubility of compound 14 in phosphate buffer was 
remarkably improved, as we expected, in comparison with compound 12l (less than 1 g/mL), 
although 14 was less soluble than 12l in 50% EtOH. Taken together, compound 14 was 
identified to be a novel KSP inhibitor with a favorable balance of potency and aqueous 
solubility. 
Compounds 5a, 6, 12i,l, 13 and 14 were tested for their inhibitory effect on the 
proliferation of cancer cell lines: lung cancer cells A549, colorectal cancer cells HCT-116, and 
breast cancer cells MCF-7 (Table 7). Cells were treated with increasing concentrations of the 
compounds, and viabilities were measured by the 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS) assay. All the tested diaryl amine derivatives were shown to be effective against these 
cell lines. In particular, thiomorpholin-3-one derivative 13 with the highest KSP inhibitory 
activity was found to be the most potent against all the cell lines tested.26 
 
3. Conclusions 
We have performed structure–activity relationship studies for the development of novel 
KSP inhibitors using carbolines 3, carbazoles 4 and diphenylamine 5a as the lead compounds. 
Unfortunately, the nonplanar analogs 7 and 8 of planar carbolines 3 and carbazoles 4 
decreased the potency for KSP inhibition. Optimization studies of diphenylamine 5a revealed 
that bridging NH group, 3-CF3 group on the right-hand phenyl group, and the lactam amide 
group at the 4-position on the left-hand phenyl group contributed to the potent KSP inhibitory 
activity. Further investigations provided novel KSP inhibitors 13 with the most potent 





4.1.1. General methods 
1H NMR spectra were recorded using a JEOL AL-400 or a JEOL ECA-500 spectrometer. 
Chemical shifts are reported in δ (ppm) relative to Me4Si as an internal standard. 13C NMR 
spectra were referenced to the residual DMSO signal. Exact mass (HRMS) spectra were 
recorded on a JMS-HX/HX 110A mass spectrometer. Melting points were measured by a hot 
stage melting point apparatus (uncorrected). For flash chromatography, Wakogel C-300E 
(Wako) or Chromatorex NH was employed. For analytical HPLC, a Cosmosil 5C18-ARII 
column (4.6 x 250 mm, Nacalai Tesque, Inc., Kyoto, Japan) was employed with a linear 
gradient of CH3CN containing 0.1% (v/v) TFA at a flow rate of 1 mL/min on a Shimadzu 
LC-10ADvp (Shimadzu Corp., Ltd., Kyoto, Japan), and eluting products were detected by UV 
at 254 nm. The purity of the compounds was determined by combustion analysis or HPLC 
analysis (> 95%). 
 
4.1.2. General procedure of N-arylation for preparation of diaryl amine compounds: 
synthesis of 6-{[3-(trifluoromethoxy)phenyl]amino}-3,4-dihydroquinolin-2(1H)-one (11i) 
Toluene (4.5 mL) was added to a flask containing 6-bromo-3,4-dihydroquinolin-2(1H)-one 
(300 mg, 1.33 mmol), 3-(trifluoromethoxy)aniline (231 L, 1.73 mmol), Pd2(dba)3 (15.2 mg, 
0.02 mmol), 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl (31.6 mg, 0.07 mmol) and 
NaOt-Bu (192 mg, 2.00 mmol) under an argon atmosphere. The mixture was stirred at 100 °C 
for 9 h. After cooling, the reaction mixture was diluted with EtOAc, and filtered through a pad 
of Celite. The filtrate was concentrated in vacuo. Crude material was purified by flash 
chromatography with n-hexane/EtOAc (2:3) to afford the desired diaryl amine 11i (292 mg, 
68% yield): pale yellow solid; mp 160-162 C; IR (neat) cm-1: 1667 (C=O), 3219 (NH), 3315 
(NH); 1H NMR (500 MHz, DMSO-d6) δ 2.43 (t, J = 6.9 Hz, 2H; CH2), 2.85 (t, J = 6.9 Hz, 
2H; CH2), 6.63 (d, J = 8.0 Hz, 1H; Ar), 6.79 (s, 1H; Ar), 6.81 (d, J = 8.0 Hz, 1H; Ar), 
6.91-6.96 (m, 3H; Ar), 7.25 (t, J = 8.0 Hz, 1H; Ar), 8.25 (s, 1H; NH), 9.99 (s, 1H; NH); 13C 
NMR (125 MHz, DMSO-d6) δ 25.0, 30.4, 106.3, 109.6, 113.1, 115.8, 118.7, 119.5, 120.1 (q), 
124.7, 130.7, 133.1, 136.1, 146.9, 149.4, 169.8; Anal. calcd for C16H13F3N2O2: C, 59.63; H, 
4.07; N, 8.69. Found: C, 59.51; H, 4.12; N, 8.59. 
 
4.1.3. N1-[3-(Trifluoromethyl)phenyl]benzene-1,3-diamine (8b) 
To a stirred solution of 3-nitro-N-[3-(trifluoromethyl)phenyl]aniline 8a (190 mg, 0.67 
mmol) and ammonium formate (509 mg, 8.07 mmol) in EtOH (2.2 mL) at room temperature 
was added 10% Pd/C (35.8 mg, 0.03 mmol). The mixture was heated under reflux for 2 h. 
After cooling, the reaction mixture was diluted with EtOAc, and filtered through a pad of 
Celite. The filtrate was concentrated in vacuo. Crude material was purified by flash 
chromatography with n-hexane/EtOAc (3:1) to afford compound 8b (165 mg, 97%): brown 
oil; IR (neat) cm-1: 3035 (NH), 3377 (NH); 1H NMR (400 MHz, DMSO-d6)  4.96 (s, 2H; 
NH2), 6.19 (d, J = 8.0 Hz, 1H; Ar), 6.28 (d, J = 8.0 Hz, 1H; Ar), 6.37 (s, 1H; Ar), 6.92 (t, J = 
8.0 Hz, 1H; Ar), 7.01 (d, J = 8.0 Hz, 1H; Ar), 7.22 (s, 1H; Ar), 7.25 (d, J = 8.2 Hz, 1H; Ar), 
7.37 (t, J = 8.0 Hz, 1H; Ar), 8.13 (s, 1H; NH); 13C NMR (125 MHz, DMSO-d6)  104.0, 106.5, 
107.8, 111.3, 114.3, 118.8, 124.3 (q), 129.6, 129.8 (q), 130.0, 142.5, 145.2, 149.7; HRMS 
(FAB): m/z calcd for C13H11F3N2 (M+) 252.0874; found: 252.0874. 
 
4.1.4. 1-(3-{[3-(Trifluoromethyl)phenyl]amino}phenyl)urea (8c) 
To a stirred solution of N1-[3-(trifluoromethyl)phenyl]benzene-1,3-diamine 8b (80.0 mg, 
0.32 mmol) in AcOH (4.0 mL) was added KOCN (77.2 mg, 0.95 mmol) and water (80.0 L). 
The reaction mixture was stirred at room temperature for 18 h, then evaporated to dryness 
under vacuum. Crude material was purified by flash chromatography with amino silica gel 
with CHCl3/MeOH (20:1 to 10:1) to afford compound 8c (31.9 mg, 34% yield): yellow oil; IR 
(neat) cm-1: 1661 (C=O), 3225 (NH), 3351 (NH); 1H NMR (500 MHz, DMSO-d6)  5.82 (br, 
2H; NH2), 6.66 (d, J = 8.0 Hz, 1H; Ar), 6.84 (d, J = 8.0 Hz, 1H; Ar), 7.06 (d, J = 8.0 Hz, 1H; 
Ar), 7.12 (t, J = 8.0 Hz, 1H; Ar), 7.28 (s, 1H; Ar), 7.30 (d, J = 8.0 Hz, 1H; Ar), 7.41 (s, 1H; 
Ar), 7.42 (t, J = 8.0 Hz, 1H; Ar), 8.50 (br, 2H; NH); 13C NMR (125 MHz, DMSO-d6)  107.4, 
110.7, 110.9, 111.5, 114.8, 118.9, 124.2 (q), 129.3, 129.8 (q), 130.1, 141.5, 142.2, 144.6, 
155.8; HRMS (FAB): m/z calcd for C14H12F3N3O (M+) 295.0932; found: 295.0926. 
 
4.1.5. 6-[(3-Hydroxyphenyl)amino]-3,4-dihydroquinolin-2(1H)-one (11j) 
A suspension of 6-[(3-methoxyphenyl)amino]-3,4-dihydroquinolin-2(1H)-one 11h (500 mg, 
1.86 mmol) in dry CH2Cl2 (5 mL) was cooled to -78 °C and then BBr3 (7.45 mL of 1 M 
solution in CH2Cl2, 7.45 mmol) was added. After the mixture was stirred for 30 min at -78 °C, 
the stirring was continued for additional 18 h at room temperature. The reaction was quenched 
by addition of water (12 mL), and CH2Cl2 was removed under reduced pressure. The aqueous 
solution was neutralized by addition of aqueous NaOH, and then extracted three times with 
EtOAc. The organic layer was washed with brine, and dried over Na2SO4. The organic solvent 
was removed under reduced pressure and the crude residue was purified by flash 
chromatography with n-hexane/EtOAc (1:3) to afford compound 11j (232 mg, 49% yield): 
brown needle crystal; mp 213-214 C; IR (neat) cm-1: 1651 (C=O), 3222 (NH), 3321 (NH); 
1H NMR (500 MHz, DMSO-d6)  2.41 (t, J = 7.4 Hz, 2H; CH2), 2.81 (t, J = 7.4 Hz, 2H; CH2), 
6.15 (d, J = 8.0 Hz, 1H; Ar), 6.38 (d, J = 8.0 Hz, 1H; Ar), 6.39 (s, 1H; Ar), 6.74 (d, J = 8.0 Hz, 
1H; Ar), 6.85 (d, J = 8.0 Hz, 1H; Ar), 6.89 (s, 1H; Ar), 6.94 (t, J = 8.0 Hz, 1H; Ar), 7.77 (s, 
1H; NH), 9.07 (s, 1H; OH), 9.89 (s, 1H; NH); 13C NMR (125 MHz, DMSO-d6)  25.1, 30.5, 
102.2, 106.0, 106.6, 115.6, 117.4, 118.2, 124.4, 129.7, 131.7, 137.7, 145.8, 158.1, 169.7; Anal. 
calcd for C15H14N2O2: C, 70.85; H, 5.55; N, 11.02. Found: C, 71.11; H, 5.59; N, 10.89. 
 
4.1.6. 6-[(3-Aminophenyl)amino]-3,4-dihydroquinolin-2(1H)-one (11l) 
To a stirred solution of 6-[(3-nitrophenyl)amino]-3,4-dihydroquinolin-2(1H)-one 11k (62.0 
mg, 0.22 mmol) in AcOH (2.2 mL) at room temperature was added zinc powder (102 mg, 
1.56 mmol) portionwise. After being stirred at room temperature for 1 h, the reaction mixture 
was filtered through a pad of Celite and concentrated under vacuum. The residue was diluted 
with EtOAc, and the whole was washed with saturated NaHCO3, brine, and dried over 
Na2SO4. The organic solvent was removed under reduced pressure and the crude residue was 
purified by flash chromatography with n-hexane/EtOAc (1:8) to afford compound 11l (41.6 
mg, 75% yield): pale yellow solid; mp 196-198 C; IR (neat) cm-1: 1662 (C=O), 3221 (NH), 
3344 (NH); 1H NMR (500 MHz, DMSO-d6) δ 2.40 (t, J = 7.4 Hz, 2H; CH2), 2.80 (t, J = 7.4 
Hz, 2H; CH2), 4.93 (br, 2H; NH2), 6.00 (d, J = 8.0 Hz, 1H; Ar), 6.15 (d, J = 8.0 Hz, 1H; Ar), 
6.24 (s, 1H; Ar), 6.72 (d, J = 8.0 Hz, 1H; Ar), 6.80 (d, J = 8.0 Hz, 1H; Ar), 6.83 (d, J = 8.0 Hz, 
1H; Ar), 6.86 (s, 1H; Ar), 7.58 (s, 1H; NH), 9.87 (s, 1H; NH); 13C NMR (125 MHz, 
DMSO-d6) δ 25.2, 30.5, 101.4, 104.5, 105.7, 115.5, 116.9, 117.7, 124.3, 129.3, 131.2, 138.3, 
145.0, 149.2, 169.6; HRMS (FAB): calcd for C15H15N3O (M+) 253.1215; found: 253.1213. 
 
4.1.7. 3-[(2-Oxo-1,2,3,4-tetrahydroquinolin-6-yl)amino]benzoic acid (11n) 
To a solution of methyl 3-[(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)amino]benzoate 11m 
(400 mg, 1.35 mmol) in 5.2 mL of MeOH/H2O (3:1 v/v) was added LiOH·H2O (170 mg, 4.05 
mmol) at 0 °C, then the solution was warmed to 50 °C. After 1 h, the reaction mixture was 
acidified to below pH 2 using 1 M HCl, then EtOAc and brine were added to the mixture. The 
organic extracts were washed with brine and dried over Na2SO4. The organic solvent was 
removed under reduced pressure to afford compound 11n (366 mg, 96% yield): white solid; 
mp 259-261 C; IR (neat) cm-1: 1656 (C=O), 1684 (C=O), 3203 (NH), 3326 (NH); 1H NMR 
(500 MHz, DMSO-d6) δ 2.43 (t, J = 7.4 Hz, 2H; CH2), 2.85 (t, J = 7.4 Hz, 2H; CH2), 6.81 (d, 
J = 8.0 Hz, 1H; Ar), 6.93 (d, J = 8.0 Hz, 1H; Ar), 6.94 (s, 1H; Ar), 7.17 (d, J = 8.0 Hz, 1H; Ar), 
7.27-7.31 (m, 2H; Ar), 7.53 (s, 1H; Ar), 8.12 (s, 1H; NH), 9.98 (s, 1H; NH), 12.78 (br, 1H; 
CO2H); 13C NMR (125 MHz, DMSO-d6) δ 25.1, 30.4, 115.5, 115.8, 118.1, 118.9, 119.0, 119.2, 
124.6, 129.3, 131.7, 132.6, 136.9, 145.2, 167.6, 169.8; HRMS (FAB): m/z calcd for 
C16H14N2O3 (M+) 282.1004; found: 282.1011. 
 
4.1.8. 7-{[3-(Trifluoromethyl)phenyl]amino}quinolin-2(1H)-one (12c) 
AcOH (1.0 mL) was added to a flask containing 
7-{[3-(trifluoromethyl)phenyl]amino)}-3,4-dihydroquinolin-2(1H)-one 12a (80.0 mg, 0.26 
mmol) and Pd(OAc)2 (22.4 mg, 0.10 mmol) and an oxygen balloon was connected to the 
reaction vessel. After stirring for 2 h at 115 °C, the reaction mixture was cooled to room 
temperature and concentrated in vacuo. The residue was purified by flash chromatography 
with n-hexane/EtOAc (1:3 to 1:5) to afford 12c (34.1 mg, 43% yield): white solid; mp 
177–179 C; IR (neat) cm-1: 1655 (C=O), 3452 (NH); 1H NMR (500 MHz, DMSO-d6) δ 6.24 
(d, J = 9.2 Hz, 1H; C=CH), 6.88 (dd, J = 8.0, 2.3 Hz, 1H; Ar), 7.06 (d, J = 2.3 Hz, 1H; Ar), 
7.23 (d, J = 8.0 Hz, 1H; Ar), 7.41 (s, 1H; Ar), 7.45 (d, J = 8.0 Hz, 1H; Ar), 7.50–7.53 (m, 2H; 
Ar), 7.75 (d, J = 9.2 Hz, 1H; C=CH), 8.99 (s, 1H; NH), 11.53 (s, 1H; NH); 13C NMR (125 
MHz, DMSO-d6) δ 99.7, 112.3, 113.1, 113.5, 116.7, 117.7, 121.0, 124.1 (q), 129.0, 130.0 (q), 
130.4, 139.8, 140.5, 142.9, 144.5, 162.2; HRMS (FAB): m/z calcd for C16H11F3N2O [M + H]+ 
305.0902; found: 305.0905. 
 
4.1.9. 6-{[3-(Trifluoromethyl)phenyl]amino}-3,4-dihydroquinoline-2(1H)-thione (12k) 
To a stirred solution of 6-{[3-(trifluoromethyl)phenyl]amino}-3,4-dihydroquinolin- 
2(1H)-one 5a (50.0 mg, 0.16 mmol) in toluene (1.0 mL) was added Lawesson’s reagent (33.0 
mg, 0.08 mmol) under an argon atmosphere. After stirring for 30 min at 110 °C, the reaction 
mixture was cooled to room temperature and concentrated in vacuo. The residue was purified 
by flash chromatography with n-hexane/EtOAc (3:1) to afford 12k (51.4 mg, 100% yield): 
yellow solid; mp 195–196 C; IR (neat) cm-1: 1499 (C=S), 3361 (NH); 1H NMR (500 MHz, 
DMSO-d6) δ 2.77 (t, J = 8.0 Hz, 2H; CH2), 2.90 (t, J = 8.0 Hz, 2H; CH2), 6.97 (s, 1H; Ar), 
6.98 (d, J = 8.0 Hz, 1H; Ar), 7.04 (d, J = 8.0 Hz, 1H; Ar), 7.06 (d, J = 8.0 Hz, 1H; Ar), 7.20 (s, 
1H; Ar), 7.27 (d, J = 8.0 Hz, 1H; Ar), 7.41 (d, J = 8.0 Hz, 1H; Ar), 8.49 (s, 1H; NH), 12.15 (s, 
1H; NH); 13C NMR (125 MHz, DMSO-d6) δ 24.0, 38.9, 111.4, 114.9, 117.0, 117.3, 118.3, 
118.5, 124.3 (q), 126.6, 130.0 (q), 130.3, 131.3, 138.3, 144.9, 197.3; HRMS (FAB): m/z calcd 




Following the general procedure for 11i, compound 13 (48.5 mg, 12% yield) was 
synthesized from 7-bromo-2H-benzo[b][1,4]thiazin-3(4H)-one and 2-amino-4- 
(trifluoromethyl)pyridine: white solid; mp 217–218 C; IR (neat) cm-1: 1688 (C=O), 3194 
(NH); 1H NMR (500 MHz, DMSO-d6) δ 3.45 (s, 2H; CH2), 6.92 (d, J = 8.6 Hz, 1H; Ar), 6.99 
(d, J = 5.2 Hz, 1H; Ar), 7.03 (s, 1H; Ar), 7.33 (dd, J = 8.6, 1.7 Hz, 1H; Ar), 7.81 (d, J = 1.7 Hz, 
1H; Ar), 8.37 (d, J = 5.2 Hz, 1H; Ar), 9.43 (s, 1H; NH), 10.44 (s, 1H; NH); 13C NMR (125 
MHz, DMSO-d6) δ 29.1, 106.2, 108.6, 117.1, 117.5, 117.7, 119.3, 123.0 (q), 131.7, 135.9, 





Following the general procedure for 11i, compound 14 (16.7 mg, 18% yield) was 
synthesized from 7-bromo-1,3,4,5-tetrahydro-2H-benzo[b]azepin-2-one and 
2-amino-4-(trifluoromethyl)pyridine: pale yellow solid; mp 185–187 C; IR (neat) cm-1: 1688 
(C=O), 2936 (NH); 1H NMR (500 MHz, DMSO-d6) δ 2.09–2.16 (m, 4H; CH2  2), 2.67 (t, J 
= 6.9 Hz, 2H; CH2), 6.92 (d, J = 8.0 Hz, 1H; Ar), 6.98 (d, J = 5.2 Hz, 1H; Ar), 7.07 (s, 1H; Ar), 
7.53 (d, J = 8.0 Hz, 1H; Ar), 7.55 (s, 1H; Ar), 8.37 (d, J = 5.2 Hz, 1H; Ar), 9.36 (s, 1H; NH), 
9.42 (s, 1H; NH); 13C NMR (125 MHz, DMSO-d6) δ 27.8, 30.1, 32.7, 106.0, 108.4, 117.4, 
119.6, 121.9, 122.0, 123.0 (q), 132.7, 134.1, 137.4, 137.5 (q), 149.3, 156.3, 173.1; HRMS 
(FAB): m/z calcd for C16H14F3N3O (M+) 321.1089; found: 321.1092. 
 
4.1.12. 6-[3-(Trifluoromethyl)phenoxy]-3,4-dihydroquinolin-2(1H)-one (17a) 
To a suspension of KOt-Bu (60.5 mg, 0.54 mmol) in DMF (2.1 mL) was added 
6-hydroxy-3,4-dihydroquinolin-2(1H)-one 15 (80.0 mg, 0.49 mmol) at 0 C and the reaction 
mixture was stirred at this temperature for 15 min. Bis(3-trifluoromethylphenyl)iodonium 
tetrafluoroborate 16 (259 mg, 0.51 mmol) was added in one portion and the reaction mixture 
was stirred at 40 C for 1 h, then quenched with H2O at 0 C and extracted into CHCl3. The 
organic layer was washed with brine, and dried over Na2SO4. The organic solvent was 
removed under reduced pressure and the crude residue was purified by flash chromatography 
with n-hexane/EtOAc (1:1) to afford compound 17a (39.9 mg, 27% yield): white solid; mp 
158-159 C; IR (neat) cm-1: 1681 (C=O), 3203 (NH); 1H NMR (500 MHz, DMSO-d6) δ 2.44 
(t, J = 7.4 Hz, 2H; CH2), 2.87 (t, J = 7.4 Hz, 2H; CH2), 6.91 (s, 2H; Ar), 6.99 (s, 1H; Ar), 
7.20-7.23 (m, 2H; Ar), 7.42 (d, J = 8.0 Hz, 1H; Ar), 7.58 (t, J = 8.0 Hz, 1H; Ar), 10.12 (s, 1H; 
NH); 13C NMR (125 MHz, DMSO-d6) δ 24.7, 30.0, 113.6, 116.3, 118.7, 119.1, 119.5, 121.0, 
123.7 (q), 125.7, 130.6 (q), 131.2, 135.3, 149.6, 158.4, 169.9; HRMS (FAB): m/z calcd for 
C16H12F3NO2 (M+) 307.0820; found: 307.0826. 
 
4.1.13. 6-{[3-(Trifluoromethyl)phenyl]thio}-3,4-dihydroquinolin-2(1H)-one (20a) 
2-Propanol (1.0 mL) was added to a flask containing 
6-mercapto-3,4-dihydroquinolin-2(1H)-one 18 (50.0 mg, 0.28 mmol), 
3-trifluoromethyliodobenzene 19a (40.4 L, 0.28 mmol), CuI (32.0 mg, 0.17 mmol), ethylene 
glycol (31.2 L, 0.56 mmol) and K2CO3 (96.7 mg, 0.70 mmol) under an argon atmosphere. 
The mixture was stirred at 80 °C for 13 h. After cooling, the reaction mixture was diluted with 
EtOAc, and filtered through a pad of Celite. The filtrate was concentrated in vacuo. Crude 
material was purified by flash chromatography with n-hexane/EtOAc (3:2) to afford 
compound 20a (6.2 mg, 7% yield): white solid; mp 102-104 C; IR (neat) cm-1: 1676 (C=O), 
3387 (NH); 1H NMR (500 MHz, DMSO-d6) δ 2.53 (t, J = 7.4 Hz, 2H; CH2), 2.96 (t, J = 7.4 
Hz, 2H; CH2), 7.00 (d, J = 8.0 Hz, 1H; Ar), 7.40 (d, J = 8.0 Hz, 1H; Ar), 7.42-7.45 (m, 2H; 
Ar), 7.49 (s, 1H; Ar), 7.58-7.59 (m, 2H; Ar), 10.34 (s, 1H; NH); 13C NMR (125 MHz, 
DMSO-d6) δ 24.4, 30.0, 116.4, 122.4, 122.6, 123.0, 123.7 (q), 125.4, 129.9 (q), 130.3, 131.0, 
133.5, 133.7, 139.5, 140.1, 170.1; HRMS (FAB): m/z calcd for C16H12F3NOS (M+) 323.0592; 
found: 323.0591. 
 
4.2. KSP ATPase assay 
The microtubules-stimulated KSP ATPase reaction was performed in a reaction buffer [20 
mM PIPES-KOH (pH 6.8), 25 mM KCl, 2 mM MgCl2, 1 mM EGTA-KOH (pH 8.0)] 
containing 38 nM of the bacteria-expressed KSP motor domain (1369) fused to histidine-tag 
at the carboxyl-terminus and 350 nM microtubules in 96-well half-area plates (Corning). Each 
chemical compound in DMSO at different concentrations was diluted 12.5-fold with the 
chemical dilution buffer [10 mM Tris-OAc (pH7.4), 0.04% (v/v) NP-40]. After pre-incubation 
of 9.7 L of the enzyme solution with 3.8 L of each chemical solution at 25 °C for 30 min, 
the ATPase reaction was initiated by the addition of 1.5 L of 0.3 mM ATP solution, and 
followed by incubation at 25 °C for further 15 min. The reaction was terminated by the 
addition of 15 L of the Kinase-Glo Plus reagent (Promega). The ATP consumption in each 
reaction was measured as the luciferase-derived luminescence by ARVO Light (PerkinElmer). 
At least three experiments were performed per condition and the averages and standard 
deviations of inhibition rates in each condition were evaluated to determine IC50 values using 
the GraphPad Prism software. 
 
4.3. Growth inhibition assay 
A549, HCT-116 and MCF-7 cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM, Sigma), McCoy’s 5A medium (GIBCO) and Eagle's minimal essential medium 
(EMEM, Wako), respectively, supplemented with 10% (v/v) fetal bovine serum at 37 °C in a 
5% CO2-incubator. Growth inhibition assays using these cells were performed in 96-well 
plates (BD Falcon). A549, HCT-116 and MCF-7 cells were seeded at 500, 5000 and 5000 
cells/well in 50 L of culture media, respectively, and were cultured for 6 h. Chemical 
compounds in DMSO were diluted 250-fold with the culture medium in advance. Following 
the addition of 40 L of the fresh culture medium to the cell cultures, 30 L of the chemical 
diluents were also added. The final volume of DMSO in the medium was equal to 0.1% (v/v). 
The cells under chemical treatment were incubated for further 72 h. The wells in the plates 
were washed twice with the cultured medium without phenol-red. After 1 h incubation with 
100 L of the medium, the cell culture in each well was supplemented with 20 L of the MTS 
reagent (Promega), followed by incubation for additional 40 min. Absorbance at 490 nm of 
each well was measured using a Wallac 1420 ARVO SX multilabel counter (Perkin Elmer). At 
least three experiments were performed per condition and the averages and standard 
deviations of inhibition rates in each condition were evaluated to determine IC50 values using 
the GraphPad Prism software. 
 
4.4. Thermodynamic solubility in aqueous solution 
An equal volume of a mixture of 1/15 M phosphate buffer (pH 7.4, 0.5 mL) and EtOH (0.5 
mL), or 1/15 M phosphate buffer (pH 7.4, 1.0 mL) was added to a compound in a vial. The 
suspension was then shaken for 48 h at 25 C, and undissolved material was separated by 
filtration. m-Cresol was added as an internal standard (final concentration: 0.05 mg/mL) and 
the mixture was diluted in DMF and injected onto the HPLC column. The peak area ratio of 
the sample to the standard was recorded by UV detection at 254 nm. The concentration of the 
sample solution was calculated using a previously determined calibration curve, corrected for 
the dilution factor of the sample. 
 
4.5. Molecular modeling 
Docking calculations for compound 11d were performed using a similar protocol in our 
previous research16 based on the crystal structure of the KSP-inhibitor complex (PDB ID: 
3ZCW).27 The protonation states of the amino acid residues of KSP and the direction of the 
hydrogen atoms involved in the hydrogen bonds were assigned using the Protonate3D 
algorithm28 implemented in MOE.29 The 4/6 allosteric site was chosen from the binding 
sites detected by the MOE-SiteFinder module. Docking pose generation was performed 
applying pharmacophore restraint to form hydrogen bonds with Asn271 and Leu292. The 100 
initial docked candidate poses were optimized by the MMFF94x forcefield30 and the pose 
with the lowest binding energy (Ebind) estimated by the MM/GBVI method31 was adopted as 
the predicted binding mode. 
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R = NO2R = NH2R = NHCONH2  
Figure 2. Design of novel KSP inhibitors 7, 8 with diaryl amine scaffolds. 
 
 




Figure 4. Design of novel diaryl amine-type KSP inhibitors 13 and 14. 
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Scheme 1. Synthesis of diaryl amine derivatives. Reagents and conditions: (a) Pd2(dba)3, 
biaryl phosphine ligand, NaOt-Bu, toluene, 100 C; (b) KOt-Bu, DMF, 40 °C; (c) CuI, 
ethylene glycol, K2CO3, 2-propanol, 80 °C; (d) Pd/C, HCO2NH4, EtOH, reflux; (e) KOCN, 
AcOH, H2O, rt; (f) BBr3, CH2Cl2, rt; (g) Zn, AcOH, rt; (h) LiOH·H2O, MeOH, H2O, 50 C; 
(i) Lawesson’s reagent, toluene, reflux; (j) Pd(OAc)2, O2, AcOH, 115 C. 
Table 1. KSP inhibitory activities and thermodynamic aqueous solubility of diaryl amines 
with a pyridine ring and the related compounds. 





(pH 7.4) (g/mL) 
 1   
 3a 0.052 0.472 <1 
 3b 0.095 1.76 3.16 
 7a >6.3
d 14.3 10.8 
 7b >6.3 24.0 264 
aInhibition of microtubule-activated KSP ATPase activity. bIC50 values were derived from the 
dose-response curves generated from triplicate data points. cSolubility in an equal volume of 
EtOH and 1/15 M phosphate buffer (pH 7.4).  dIC50 was ≈7.0 M. 
Table 2. KSP inhibitory activities of diphenylamines with a nitro, amino or urea group and the 
related carbazoles. 
compound R KSP ATPase IC50 (M)a,b 
 
4b NH2 0.27 
4c NHCONH2 0.085 
    
 
4d NO2 0.043 
4e NH2 0.55 
4f NHCONH2 0.12 
    
 
8a NO2 >6.3 
8b NH2 >6.3 
8c NHCONH2 >6.3 




8d NO2 3.2 
8e NH2 >6.3 
8f NHCONH2 0.39 
aInhibition of microtubule-activated KSP ATPase activity. bIC50 values were derived from the 
dose-response curves generated from triplicate data points. 
 
Table 3. KSP inhibitory activities of dihydroquinolinone derivatives. 
compound  X KSP ATPase IC50 (M)a,b 
 
5a NH 0.045 
17a O 2.0 
20a S >6.3 
 
5b NH 0.33 
17b O >6.3 
20b S >6.3 
 
5c  >6.3 
aInhibition of microtubule-activated KSP ATPase activity. bIC50 values were derived from the 
dose–response curves generated from triplicate data points. 
 
Table 4. KSP inhibitory activities of diphenylamines with a 3-substituent or 3,5-substituents 
on the right-hand phenyl group. 
 
R  KSP ATPase IC50 (M)a,b R  
KSP ATPase 
IC50 (M)a,b 
3-CF3 5a 0.045 3-OMe 11h >6.3 
H 11a >6.3 3-OCF3 11i 1.2 
3-Et 11b 0.81 3-OH 11j >6.3 
3-i-Pr 11c 0.43 3-NO2 11k 0.44 
3-t-Bu 11d 0.16 3-NH2 11l >6.3 
3,5-di-CF3 11e >6.3 3-CO2Me 11m >6.3 
3-Ph 11f >6.3 3-CO2H 11n >6.3 
3-OPh 11g >6.3    
aInhibition of microtubule-activated KSP ATPase activity. bIC50 values were derived from the 
dose–response curves generated from triplicate data points. 
 
Table 5. KSP inhibitory activities of diphenylamines with a heterocycle on the left-hand 
phenyl group. 
 




5a 0.045 12h 0.29 
 12a >6.3 12i 0.051 
 
12b >6.3 12j >6.3 






12e 3.6 12m 0.43 
 
12f >6.3 12n 0.92 
 
12g 0.81    
aInhibition of microtubule-activated KSP ATPase activity. bIC50 values were derived from the 
dose–response curves generated from triplicate data points. 
Table 6. KSP inhibitory activities and physicochemical properties of diaryl amine derivatives 5a, 6, 







NH CF3  
5a 12i 12l 
KSP ATPase  
IC50 (M)a,b 
0.045 0.051 0.050 
Solubility in 50% EtOH 
(mg/mL)c 1.80 1.70 7.39 
Solubility in phosphate buffer 
(pH 7.4) (g/mL) <1 <1 <1 
melting point (C) 190 166 140 
ClogPd 4.2 4.0 4.4 






6 13 14 
KSP ATPase  
IC50 (M)a,b 
0.068 0.035 0.050 
Solubility in 50% EtOH 
(mg/mL)c 3.51 0.669 4.82 
Solubility in phosphate buffer 
(pH 7.4) (g/mL) 6.12 1.11 8.07 
melting point (C) 177 217 185 
ClogPd 3.4 3.2 3.6 
HPLC retention time (min)e 7.0 13.8 10.8 
aInhibition of microtubule-activated KSP ATPase activity. bIC50 values were derived from the 
dose–response curves generated from triplicate data points. cSolubility in 50% EtOH [an equal 
volume of EtOH and 1/15 M phosphate buffer (pH 7.4)]. dCLogP values were calculated with 
ChemBioDraw Ultra 12.0. eHPLC analysis was carried out on a Cosmosil 5C18-ARII column (4.6 
 250 mm) and the material eluted by a linear MeCN gradient (30-70% over 40 min) in 0.1% TFA; 
flow rate of 1 mL/min.aInhibition of microtubule-activated KSP ATPase activity. bIC50 values were 
derived from the dose–response curves generated from triplicate data points. cSolubility in 50% 
EtOH [an equal volume of EtOH and 1/15 M phosphate buffer (pH 7.4)]. dCLogP values were 
calculated with ChemBioDraw Ultra 12.0. eHPLC analysis was carried out on a Cosmosil 
5C18-ARII column (4.6  250 mm) and the material eluted by a linear MeCN gradient (30-70% 
over 40 min) in 0.1% TFA; flow rate of 1 mL/min. 
Table 7. Inhibitory effects on cell proliferation of diaryl amine-type KSP inhibitors toward 
A549, HCT-116 and MCF-7. 
compound IC50 (M)
a 
A549 HCT-116 MCF-7 
5a 4.2 8.9 11 
6 2.5 4.4 8.0 
12i 4.1 6.8 6.5 
12l 4.5 5.7 3.9 
13 1.5 2.6 2.8 
14 5.0 6.5 9.1 
aIC50 values were derived from the dose–response curves generated from triplicate data 
points. 
